

# Jyoti D Patel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6008525/publications.pdf>

Version: 2024-02-01

62  
papers

3,291  
citations

331670

21  
h-index

161849

54  
g-index

62  
all docs

62  
docs citations

62  
times ranked

4515  
citing authors

#	ARTICLE	IF	CITATIONS
1	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	10.7	608
2	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€“Selected Advanced Nonâ€“Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	1.6	348
3	PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4349-4357.	1.6	326
4	Lung Cancer in US Women. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1763.	7.4	220
5	Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3284-3289.	1.6	168
6	Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2863-2871.	1.6	158
7	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Nonâ€“Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021, 11, 1688-1699.	9.4	154
8	Lung Cancer in Women. <i>Journal of Clinical Oncology</i> , 2005, 23, 3212-3218.	1.6	137
9	Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1610-1623.	10.7	136
10	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. <i>Lung Cancer</i> , 2019, 128, 105-112.	2.0	126
11	Management of Stage III Nonâ€“Small-Cell Lung Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 1356-1384.	1.6	104
12	Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for <i>EGFR</i>-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Journal of Clinical Oncology</i> , 2015, 33, 1666-1673.	1.6	99
13	Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2014, 32, 129-160.	1.6	74
14	Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, 252-256.	2.6	65
15	CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 20059.	3.3	53
16	A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 130-140.	1.1	49
17	A Phase 1â€“2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1559-1569.	1.1	41
18	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	1.1	40

#	ARTICLE	IF	CITATIONS
19	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. <i>Cancers</i> , 2021, 13, 3164.	3.7	35
20	Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100418.	3.0	29
21	A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-13. <i>Cancer</i> , 2017, 123, 303-311.	4.1	23
22	Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 4-15.	3.2	20
23	The use of varenicline to treat nicotine dependence among patients with cancer. <i>Psycho-Oncology</i> , 2017, 26, 1526-1534.	2.3	19
24	Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	18
25	Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 576314.	2.8	17
26	Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. <i>Lung Cancer</i> , 2021, 161, 180-188.	2.0	14
27	Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center. <i>Oncotarget</i> , 2019, 10, 5817-5823.	1.8	14
28	Early Stage Lung Cancer Detection in Systemic Sclerosis Does Not Portend Survival Benefit: A Cross Sectional Study. <i>PLoS ONE</i> , 2015, 10, e0117829.	2.5	13
29	Patterns and Predictors of Chemotherapy Use for Resected Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2016, 101, 533-540.	1.3	13
30	A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8036-8036.	1.6	13
31	Chemotherapy and Targeted Therapeutics as Maintenance of Response in Advanced Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2014, 41, 93-100.	2.2	12
32	Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3594-3594.	1.6	12
33	Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3610-3610.	1.6	11
34	Randomized phase I trial to evaluate concurrent sequential nivolumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV non-small cell lung cancer (COSINR Study).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9616-9616.	1.6	11
35	Leptomeningeal metastases: the future is now. <i>Journal of Neuro-Oncology</i> , 2022, 156, 443-452.	2.9	11
36	Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care. <i>Clinical Lung Cancer</i> , 2018, 19, e823-e830.	2.6	10

#	ARTICLE	IF	CITATIONS
37	Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers. <i>Cancer Research</i> , 2021, 81, CT011-CT011.	0.9	10
38	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	1.1	9
39	Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. <i>JCO Precision Oncology</i> , 2022, , .	3.0	9
40	Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-“Small-Cell Lung” Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). <i>Clinical Lung Cancer</i> , 2020, 21, 520-526.	2.6	8
41	Reversible Nyctalopia and Retinopathy in a Patient With Metastatic Cancer Treated With Anti-“Heat Shock Protein 90 Therapy. <i>JAMA Ophthalmology</i> , 2014, 132, 899.	2.5	7
42	Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-“Small-Cell Lung Cancer: A Multicenter Case Series. <i>JCO Precision Oncology</i> , 2018, 2, 1-10.	3.0	7
43	Optimal First-Line and Maintenance Treatments for Advanced-Stage Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 889-897.	4.9	6
44	Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 200-208.	2.6	6
45	Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8073-8073.	1.6	6
46	Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. <i>Current Opinion in Oncology</i> , 2006, 18, 609-614.	2.4	4
47	Lung Cancer: A Biologically Different Disease in Women?. <i>Women's Health</i> , 2009, 5, 685-691.	1.5	4
48	Role of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Bronchoalveolar Carcinoma. <i>Clinical Lung Cancer</i> , 2004, 6, S43-S47.	2.6	3
49	A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3083-3083.	1.6	3
50	Patient-reported outcomes from POINTBREAK: The randomized, open-label, phase III study of pemetrexed (pem) + carboplatin (cb) + bevacizumab (bev) followed by maintenance pem + bev versus paclitaxel (pac) + cb + bev followed by maintenance bev in patients with stage IIIB or IV nonsquamous non-small cell lung cancer (NS-NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 53-53.	1.6	2
51	Biomarker testing methods in breast, gastric, and lung cancers: A benchmarking survey of NCI cancer centers.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22093-e22093.	1.6	2
52	Induction chemotherapy for resectable non-small-cell lung cancer. <i>Oncology</i> , 2004, 18, 1591-602; discussion 1602-3, 1606, 1611-2.	0.5	2
53	A randomized double-blind phase II trial of platinum (P) plus etoposide (E) with or without concurrent ZD6474 (Z) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC): Hoosier Oncology Group LUN06-113.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7506-7506.	1.6	1
54	Tepotinib in patients (pts) with NSCLC with <i>MET</i> exon 14 ( <i>MET</i> ex14) skipping: Health-related quality of life (HRQoL).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9575-9575.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Cytokine Targeted Treatments for Lung Cancer. , 2005, 126, 289-311.		0
56	Treatment of Non-Small Cell Lung Cancer: Focus on Pemetrexed Disodium. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S5262.	0.4	0
57	Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?. Cancer, 2018, 124, 2878-2880.	4.1	0
58	The Rapidly Changing World of Thoracic Oncology. Thoracic Surgery Clinics, 2020, 30, xiii-xiv.	1.0	0
59	The occurrence of grade 4 adverse events and survival outcomes in patients with nonsquamous non-small cell lung cancer receiving bevacizumab with chemotherapy in the phase III PointBreak and AVAiL studies.. Journal of Clinical Oncology, 2013, 31, e19022-e19022.	1.6	0
60	Phase (Ph) I study of pazopanib (P) in combination with vinorelbine (V) in patients with metastatic non-small cell lung cancer (mNSCLC) and breast cancer (mBC).. Journal of Clinical Oncology, 2013, 31, e13568-e13568.	1.6	0
61	Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC).. Journal of Clinical Oncology, 2013, 31, 8012-8012.	1.6	0
62	Impact of recent clinical trials on the use of chemotherapy for resectable non-small cell lung cancer in the United States.. Journal of Clinical Oncology, 2014, 32, 6619-6619.	1.6	0